Pre-treatment risk stratification of prostate cancer patients: A critical review

Journal of the Canadian Urological Association

Volumn 6, Issue 2, 2012, Pages 121-127

  Rodrigues, George ^a   Warde, Padraig ^b   Pickles, Tom ^c   Crook, Juanita ^c   Brundage, Michael ^d   Souhami, Luis ^e   Lukka, Himu ^f  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859995934     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.11085     Document Type: Review

References (51)

1. Capitanio U, Briganti A, Gallina A, et al. Predictive models before and after radical prostatectomy. Prostate 2010;70:1371-8.
2. Chun FK, Karakiewicz PI, Briganti A, et al. A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. BJU Int 2007;99:794-800.
3. Lukka H, Warde P, Pickles T, et al. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol 2001;8:1314-22.
4. Sutcliffe P, Hummel S, Simpson E, et al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technol Assess 2009;13:iii, xi-xiii 1-219.
5. Jewett HJ. The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 1975;2:105-24.
6. Montie JE. Staging of prostate cancer: current TNM classification and future prospects for prognostic factors. Cancer 1995;75(7 Suppl):1814-8.
7. Gleason DF. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M: Urologic Pathology: The Prostate. Philadelphia, PA: Lea and Febiger; 1977:171-97.
8. Chan TY, Partin AW, Walsh PC, et al. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000;56:823-7.
9. Nguyen PL, Schultz D, Renshaw AA, et al. The impact of pathology review on treatment recommendations for patients with adenocarcinoma of the prostate. Urol Oncol 2004;22:295-9.
10. King CR, Long JP. Prostate biopsy grading errors: a sampling problem? Int J Cancer 2000;90:326-30.
11. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51.
12. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
13. Aleman M, Karakiewicz PI, Kupelian P, et al. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening. Urology 2003;62:70-4.
14. Shekarriz B, Upadhyay J, Bianco FJ Jr, et al. Impact of preoperative serum PSA level from 0 to 10 ng/ml on pathological findings and disease-free survival after radical prostatectomy. Prostate 2001;48:136-43.
15. Rodrigues G, Bae K, Roach M, et al. Impact of Ultrahigh Baseline PSA Levels on Biochemical and Clinical Outcomes in Two Radiation Therapy Oncology Group Prostate Clinical Trials. Int J Radiat Oncol Biol Phys 2010 Jul 6. [Epub ahead of print].
16. Pisansky TM, Zincke H, Suman VJ, et al. Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens. Int J Radiat Oncol Biol Phys1996;34:33-9.
17. Karakiewicz PI, Lattouf JB, Perrotte P, et al. Validation of 1997 Partin Tables' lymph node invasion predictions in men treated with radical prostatectomy in Montreal Quebec. Can J Urol 2005;12:2588-92.
18. Blute ML, Bergstralh EJ, Partin AW, et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 2000;164:1591-5.
19. Penson DF, Grossfeld GD, Li YP, et al. How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. J Urol 2002;167:1653-7.
20. Steuber T, Karakiewicz PI, Augustin H, et al. Transition zone cancers undermine the predictive accuracy of Partin table stage predictions. J Urol 2005;173:737-41.
21. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.
22. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300-5.
23. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002;52:444-52.
24. Sylvester JE, Blasko JC, Grimm PD, et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 2003;57:944-52.
25. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:25-33.
26. Chism DB, Hanlon AL, Horwitz EM, et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:380-5.
27. Zietman AL, Chung CS, Coen JJ, et al. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol 2004;171:210-4.
28. Selek U, Lee A, Levy L, et al. Utility of the percentage of positive prostate biopsies in predicting PSA outcome after radiotherapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2003;57:963-7.
29. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006;176:1415-9.
30. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8:162-200.
31. Graham J, Baker M, Macbeth F, et al. Diagnosis and treatment of prostate cancer: summary of NICE guidance. BMJ 2008;336:610-2.
32. Horwich A, Parker C, Bangma C, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:v129-33.
33. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106-31.
34. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80.
35. Prostate. In: Edge SB, Byrd DR, Compton CC, et al. eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:457-68.
36. Roach M 3rd, Weinberg V, Sandler H, et al. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? Cancer 2007;109:213-20.
37. Nanda A, Chen MH, Renshaw AA, et al. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys 2009;74:1419-23.
38. Lughezzani G, Budäus L, Isbarn H, et al. Head-to-Head Comparison of the Three Most Commonly Used Preoperative Models for Prediction of Biochemical Recurrence After Radical Prostatectomy. Eur Urol 2009;57:562-68.
39. Williams SG, Duchesne GM, Gogna NK, et al. An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk. Int J Radiat Oncol Biol Phys 2006;65:351-7.
40. Yoshioka Y, Inoue T. Prostate Risk Index (PRIX) as a new method of risk classification for clinically localized prostate cancer. Strahlenther Onkol 2007;183:490-6.
41. Cooperberg MR, Lubeck DP, Mehta SS, et al. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003;170:S21-5.
42. Nguyen PL, Chen MH, Catalona WJ, et al. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys 2009;73:659-64.
43. Cowen ME, Halasyamani LK, Kattan MW. Predicting life expectancy in men with clinically localized prostate cancer. J Urol 2006;175:99-103.
44. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;69:517-23.
45. Roach M 3rd, Weinberg V, Nash M, et al. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials. J Urol 2006;176:S16-20.
46. Beasley M, Williams SG, Pickles T, et al. Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy. Radiat Oncol 2008;3:8.
47. Roach M, Lu J, Pilepich MV, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 2000;47:609-15.
48. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 2003;21:4568-71.
49. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of threedimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000;18:3352-9.
50. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
51. National Cancer Institute. The Radiation Therapy Oncology Group (RTOG). www.rtog.org. Accessed March 5, 2012.